{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:40:18Z","timestamp":1774460418293,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01173-1","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T12:13:23Z","timestamp":1756815203000},"page":"861-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy"],"prefix":"10.1007","volume":"20","author":[{"given":"Kelvin","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arizah","family":"Bakhtiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Hota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frankie","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"3","key":"1173_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1173_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1173_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/JTO.0000000000000263","volume":"9","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345\u201353. https:\/\/doi.org\/10.1097\/JTO.0000000000000263.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1173_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40247-014-0009-0","volume":"2","author":"I Hantson","year":"2014","unstructured":"Hantson I, Dooms C, Verbeken E, Vandenberghe P, Vliegen L, Roskams T, et al. Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Transl Respir Med. 2014;2(1):9. https:\/\/doi.org\/10.1186\/s40247-014-0009-0.","journal-title":"Transl Respir Med"},{"issue":"1","key":"1173_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00432-014-1789-x","volume":"141","author":"P Krawczyk","year":"2015","unstructured":"Krawczyk P, Ramlau R, Chorostowska-Wynimko J, Powr\u00f3zek T, Lewandowska MA, Limon J, et al. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. J Cancer Res Clin Oncol. 2015;141(1):61\u20138. https:\/\/doi.org\/10.1007\/s00432-014-1789-x.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"48","key":"1173_CR6","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985\u201393. https:\/\/doi.org\/10.18632\/oncotarget.12587.","journal-title":"Oncotarget"},{"issue":"10","key":"1173_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"5","key":"1173_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2015.0071","volume":"13","author":"DS Ettinger","year":"2015","unstructured":"Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. National comprehensive cancer network. Non-small cell lung cancer, Version 6.2015. J Natl Compr Canc Netw. 2015;13(5):515\u201324. https:\/\/doi.org\/10.6004\/jnccn.2015.0071.","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl 5","key":"1173_CR9","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1\u201327. https:\/\/doi.org\/10.1093\/annonc\/mdw326.","journal-title":"Ann Oncol"},{"issue":"8","key":"1173_CR10","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1173_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"issue":"4","key":"1173_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1173_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"1173_CR14","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275.","journal-title":"Ann Oncol"},{"issue":"25","key":"1173_CR15","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0909530.","journal-title":"N Engl J Med"},{"issue":"19","key":"1173_CR16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMc2001514","volume":"382","author":"K Yan","year":"2020","unstructured":"Yan K. Osimertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(19):1863. https:\/\/doi.org\/10.1056\/NEJMc2001514.","journal-title":"N Engl J Med"},{"issue":"21","key":"1173_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"key":"1173_CR18","unstructured":"Excellence NI of C (2016) Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer | Guidance TA416| NICE. https:\/\/www.nice.org.uk\/guidance\/ta416. Accessed 8 June 2025."},{"key":"1173_CR19","unstructured":"Excellence NI of C (2020) 1 Recommendations | Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | Guidance TA653 | NICE. https:\/\/www.nice.org.uk\/guidance\/ta653\/chapter\/1-Recommendations. Accessed 8 June 2025."},{"key":"1173_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2019.01.012","volume":"130","author":"K Lee","year":"2019","unstructured":"Lee K, Kim Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, et al. Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer. 2019;130:87\u201392. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.012.","journal-title":"Lung Cancer"},{"issue":"2","key":"1173_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pulmoe.2020.11.004","volume":"27","author":"R Sa\u00fade-Conde","year":"2021","unstructured":"Sa\u00fade-Conde R, Crist\u00f3v\u00e3o-Ferreira S, Campoa E, Almodovar MT. Value of rebiopsy in advanced epidermal growth factor receptor mutated non-small cell lung cancer: real-world data. Pulmonology. 2021;27(2):177\u201380. https:\/\/doi.org\/10.1016\/j.pulmoe.2020.11.004.","journal-title":"Pulmonology"},{"issue":"1","key":"1173_CR22","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1038\/s41598-022-10288-8","volume":"12","author":"K Koyama","year":"2022","unstructured":"Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, et al. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Sci Rep. 2022;12(1):6367. https:\/\/doi.org\/10.1038\/s41598-022-10288-8.","journal-title":"Sci Rep"},{"issue":"2","key":"1173_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","volume":"40","author":"S Igawa","year":"2022","unstructured":"Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, et al. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: a prospective observational study. Invest New Drugs. 2022;40(2):430\u20137. https:\/\/doi.org\/10.1007\/s10637-021-01195-2.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1173_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jtho.2024.12.027","volume":"20","author":"T Fukui","year":"2025","unstructured":"Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, et al. A prospective phase II trial of first-line Osimertinib for patients with EGFR mutation-positive NSCLC and poor performance status (OPEN\/TORG2040). J Thorac Oncol. 2025;20(5):665\u201375. https:\/\/doi.org\/10.1016\/j.jtho.2024.12.027.","journal-title":"J Thorac Oncol"},{"key":"1173_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cllc.2020.05.019","volume":"21","author":"RGP Gijtenbeek","year":"2020","unstructured":"Gijtenbeek RGP, Damhuis RAM, Groen HJM, Wekken AJVD, Geffen WHV. Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Clin Lung Cancer. 2020;21:6. https:\/\/doi.org\/10.1016\/j.cllc.2020.05.019.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"1173_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001011","volume":"5","author":"A Pluzanski","year":"2020","unstructured":"Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open. 2020;5(6):e001011. https:\/\/doi.org\/10.1136\/esmoopen-2020-001011.","journal-title":"ESMO Open"},{"issue":"9","key":"1173_CR27","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1634\/theoncologist.2016-0331","volume":"22","author":"ZH Yao","year":"2017","unstructured":"Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, et al. Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib. Oncologist. 2017;22(9):1075\u201383. https:\/\/doi.org\/10.1634\/theoncologist.2016-0331.","journal-title":"Oncologist"},{"key":"1173_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.869390","volume":"12","author":"P-C Hsieh","year":"2022","unstructured":"Hsieh P-C, Wu Y-K, Huang C-Y, Yang M-C, Kuo C-Y, Tzeng I-S, et al. Comparison of T790M acquisition after treatment with first- and second-generation tyrosine-kinase inhibitors: a systematic review and network meta-analysis. Front Oncol. 2022;12:869390. https:\/\/doi.org\/10.3389\/fonc.2022.869390.","journal-title":"Front Oncol"},{"issue":"12","key":"1173_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1200\/JCO.23.01521","volume":"42","author":"J Remon","year":"2024","unstructured":"Remon J, Besse B, Aix SP, et al. Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non-small-cell lung cancer. J Clin Oncol. 2024;42(12):1350\u20136. https:\/\/doi.org\/10.1200\/JCO.23.01521.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1173_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337. https:\/\/doi.org\/10.1038\/s41416-019-0573-8.","journal-title":"Br J Cancer"},{"issue":"3","key":"1173_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000344","volume":"3","author":"JA Pinto","year":"2018","unstructured":"Pinto JA, Vallejos CS, Raez LE, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. 2018;3(3):e000344. https:\/\/doi.org\/10.1136\/esmoopen-2018-000344.","journal-title":"ESMO Open"},{"key":"1173_CR32","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290\u20137. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1173_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","volume":"82","author":"K Goto","year":"2013","unstructured":"Goto K, Nishio M, Yamamoto N, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013;82(1):109\u201314. https:\/\/doi.org\/10.1016\/j.lungcan.2013.07.003.","journal-title":"Lung Cancer"},{"issue":"3 Pt 1","key":"1173_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3 Pt 1):839\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1846.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1173_CR35","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13):3908\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0462.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1173_CR36","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1080\/14796694.2024.2362613","volume":"20","author":"S Kim","year":"2024","unstructured":"Kim S, Heo Y, Lee YH, Kang JH. Are 19del and L858R really different disease entities? Future Oncol. 2024;20(23):1689\u201394. https:\/\/doi.org\/10.1080\/14796694.2024.2362613.","journal-title":"Future Oncol"},{"issue":"4","key":"1173_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jtho.2024.11.032","volume":"20","author":"K Nakagawa","year":"2025","unstructured":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, et al. Relay: final overall survival for erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC. J Thorac Oncol. 2025;20(4):487\u201399. https:\/\/doi.org\/10.1016\/j.jtho.2024.11.032.","journal-title":"J Thorac Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01173-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:24:12Z","timestamp":1758720252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01173-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.Y., A.B., S.H., J.E. and F.M. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved as a clinical audit at Imperial College Healthcare NHS Trust (registration number: O&P_102). Because of the retrospective nature of the study, informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The data that support the findings of this study are not openly available owing to reasons of sensitivity and are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"K.Y. carried out study conceptualization methodology and writing\u2014original draft preparation; K.Y., A.B., S.H. and J.E. carried out data collection; K.Y. and F.M. carried out formal analysis and investigation; K.Y., A.B., S.H., J.E. and F.M. carried out writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}